294 related articles for article (PubMed ID: 37453616)
1. Optimizing metabolic stability of phosphodiesterase 5 inhibitors: Discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity.
Zuccarello E; Zhang H; Acquarone E; Pham D; Staniszewski A; Deng SX; Landry DW; Arancio O; Fiorito J
Bioorg Med Chem Lett; 2023 Aug; 92():129409. PubMed ID: 37453616
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Fiorito J; Saeed F; Zhang H; Staniszewski A; Feng Y; Francis YI; Rao S; Thakkar DM; Deng SX; Landry DW; Arancio O
Eur J Med Chem; 2013 Feb; 60():285-94. PubMed ID: 23313637
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes.
Liu J; Maisonial-Besset A; Wenzel B; Canitrot D; Baufond A; Chezal JM; Brust P; Moreau E
Eur J Med Chem; 2017 Aug; 136():548-560. PubMed ID: 28544981
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease.
Fiorito J; Vendome J; Saeed F; Staniszewski A; Zhang H; Yan S; Deng SX; Arancio O; Landry DW
J Med Chem; 2017 Nov; 60(21):8858-8875. PubMed ID: 28985058
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Liu L; Xu H; Ding S; Wang D; Song G; Huang X
Brain Res Bull; 2019 Nov; 153():223-231. PubMed ID: 31493542
[TBL] [Abstract][Full Text] [Related]
7. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Mar; 10(3):1765-1782. PubMed ID: 30525452
[TBL] [Abstract][Full Text] [Related]
8. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
9. Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18.
Wenzel B; Liu J; Dukic-Stefanovic S; Deuther-Conrad W; Teodoro R; Ludwig FA; Chezal JM; Moreau E; Brust P; Maisonial-Besset A
Bioorg Chem; 2019 May; 86():346-362. PubMed ID: 30753989
[TBL] [Abstract][Full Text] [Related]
10. Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Huang XF; Dong YH; Wang JH; Ke HM; Song GQ; Xu DF
Bioorg Med Chem Lett; 2020 May; 30(9):127097. PubMed ID: 32171616
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
13. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.
Cuadrado-Tejedor M; Garcia-Barroso C; Sánchez-Arias JA; Rabal O; Pérez-González M; Mederos S; Ugarte A; Franco R; Segura V; Perea G; Oyarzabal J; Garcia-Osta A
Neuropsychopharmacology; 2017 Jan; 42(2):524-539. PubMed ID: 27550730
[TBL] [Abstract][Full Text] [Related]
14. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
[TBL] [Abstract][Full Text] [Related]
16. Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain.
Liu J; Wenzel B; Dukic-Stefanovic S; Teodoro R; Ludwig FA; Deuther-Conrad W; Schröder S; Chezal JM; Moreau E; Brust P; Maisonial-Besset A
Pharmaceuticals (Basel); 2016 Apr; 9(2):. PubMed ID: 27110797
[TBL] [Abstract][Full Text] [Related]
17. Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
Jin F; Gong QH; Xu YS; Wang LN; Jin H; Li F; Li LS; Ma YM; Shi JS
Int J Neuropsychopharmacol; 2014 Jun; 17(6):871-81. PubMed ID: 24513083
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
J Med Chem; 2016 Oct; 59(19):8967-9004. PubMed ID: 27606546
[TBL] [Abstract][Full Text] [Related]
19. 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Mochida H; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2015 Apr; 25(7):1431-5. PubMed ID: 25754491
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions.
Kang BW; Kim F; Cho JY; Kim S; Rhee J; Choung JJ
Alzheimers Res Ther; 2022 Jul; 14(1):92. PubMed ID: 35804462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
